<DOC>
	<DOCNO>NCT00292331</DOCNO>
	<brief_summary>The purpose study test hypothesis compare efficacy cyanoacrylate injection ( GVO ) band ligation ( GVL ) treatment acute GVH liver cirrhotic patient without concomitant hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>N-Butyl-2-Cyanoacrylate Injection Versus Band Ligation Gastric Variceal Hemorrhage</brief_title>
	<detailed_description>Gastric variceal hemorrhage ( GVH ) poor prognosis esophageal variceal hemorrhage . However , data optimal treatment limited . We design prospective study compare efficacy endoscopic band ligation ( GVL ) endoscopic N-butyl-2-cyanoacrylate injection ( GVO ) . Liver cirrhotic patient without concomitant hepatocelluar carcinoma ( HCC ) patient present acute GVH randomize two treatment group . Forty-eight patient receive GVL , another 49 patient receive GVO . Both treatment equally successful control active bleeding ( 14/15 vs. 14/15 , P = 1.000 ) . More patient underwent GVL GV rebleeding ( GVL vs. GVO , 21/48 vs. 11/49 ; P = .044 ) . The 2-year 3-year cumulative rate GV rebleeding 63.1 % ( 95 % confidence interval [ CI ] , 44.5 % -81.7 % ) , 72.3 % ( 95 % CI , 51.3 % -93.3 % ) GVL 26.8 % ( 95 % CI , 12.5 % -41.1 % ) , 26.8 % ( 95 % CI , 12.5 % -41.1 % ) GVO ; P = .0143 , log-rank test . The rebleeding risk GVL sustain throughout entire follow-up period . Multivariate Cox regression indicate concomitance HCC ( relative hazard : 2.453 , 95 % CI : 1.036-5.806 , P = .041 ) treatment method ( GVL vs. GVO , relative hazard : 2.660 , 95 % CI : 1.167-6.061 , P = .020 ) independent factor predictive GV rebleeding . There difference survival two group . Severe complication due two treatment rare . In conclusion , efficacy GVL control active GVH appear difference GVO , GVO associate low GV rebleeding rate .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>* Patients age 18 80 year endoscopyproven acute gastric variceal hemorrhage ( GVH ) Cases concomitant large GV large EV , without stigmata recent bleeding Cases previous endoscopic , surgical treatment transjugular intrahepatic portosystemic shunt GVH Cases terminal illness major organ system , like heart failure , uremia , chronic obstructive pulmonary disease , nonhepatic malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>gastric varix</keyword>
	<keyword>liver cirrhosis</keyword>
	<keyword>hepatocelluar carcinoma</keyword>
	<keyword>rebleeding</keyword>
	<keyword>long-term</keyword>
</DOC>